<SEC-DOCUMENT>0000950123-11-035742.txt : 20110610
<SEC-HEADER>0000950123-11-035742.hdr.sgml : 20110610
<ACCEPTANCE-DATETIME>20110414182731
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-11-035742
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20110414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>corresp</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<P><DIV style="position: relative; float: left; width: 48%">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="y04704cy0470402.gif" alt="(LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Joel I. Papernik </B>| 212 692 6774 | jipapernik@mintz.com
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 48%">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Chrysler Center<BR>
666 Third Avenue<BR>
New York, NY 10017<BR>
212-935-3000<BR>
212-983-3115 fax<BR>
www.mintz.com
</DIV>

</DIV>
<BR clear="all"><BR>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">April&nbsp;14, 2011
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>Via EDGAR and by Federal Express</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Securities and Exchange Commission<BR>
Division of Corporation Finance

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">100 F Street, N.E.<BR>
Mail Stop 3561

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 0pt">Washington, D.C. 20549
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Re:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Cyclacel Pharmaceuticals, Inc.</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Pre-Effective Amendment No.&nbsp;1 to</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Registration Statement on Form&nbsp;S-3/A</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>As initially filed on April&nbsp;4, 2011</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Registration Number 333-173291</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentleman:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On behalf of Cyclacel Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;), we hereby file with the
Securities and Exchange Commission (the <B>&#147;Commission&#148;</B>) Pre-Effective Amendment No.&nbsp;1 to the
Registration Statement on Form S-3/A (Registration No.&nbsp;333-173291) (the &#147;<B>Amendment</B>&#148;) as initially
filed with the Commission on April&nbsp;4, 2011 (the &#147;<B>Registration Statement</B>&#148;). We are also delivering
five clean and marked complete courtesy copies of the Amendment to the attention of Johnny Gharib,
Esq. of the Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below are the Company&#146;s responses to the comments provided by the staff (the
&#147;<B>Staff</B>&#148;) of the Commission by way of a letter (the &#147;<B>Comment Letter</B>&#148;) dated April&nbsp;13, 2011, from
Jeffrey P. Riedler, Esq., Assistant Director of the Division of Corporation Finance. The Company&#146;s
responses are numbered to correspond to the comments, as set forth in the Comment Letter, which,
for convenience, we have incorporated into this response letter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>General</B></U>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Please verify that you will file forms of indenture in a pre-effective amendment for the
senior and subordinated debt securities.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Response</I></U>: The Company has filed the form of Indenture relating to senior debt
securities and the form of Indenture relating to subordinated debt securities as Exhibits 4.3
and 4.4, respectively, to the Amendment.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>We note that you are attempting to register a primary offering of your securities on Form
S-3, but the aggregate market value of the common equity held by non-affiliates appears to be
less than the $75&nbsp;million minimum required by General Instruction I.B.1. of S-3. Accordingly,
please provide us with an explanation of why you are eligible to register this offering on
Form&nbsp;S-3. If you are relying on General</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="FONT-variant: SMALL-CAPS">Boston</FONT> | <FONT style="FONT-variant: SMALL-CAPS">Washington</FONT> | <FONT style="FONT-variant: SMALL-CAPS">New York</FONT> | <FONT style="FONT-variant: SMALL-CAPS">Stamford</FONT> | <FONT style="FONT-variant: SMALL-CAPS">Los Angeles</FONT> | <FONT style="FONT-variant: SMALL-CAPS">Palo Alto</FONT> | <FONT style="FONT-variant: SMALL-CAPS">San Diego</FONT> |
<FONT style="FONT-variant: SMALL-CAPS">London</FONT>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Securities and Exchange Commission<BR>
April&nbsp;14, 2011<BR>
Page 2

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Instruction I.B.6. of S-3, please confirm this and provide the disclosure on the outside
front cover of the prospectus required by Instruction 7 to I.B.6.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Response</I></U>: The Company relied on General Instruction I.B.6. in determining that the
Company was eligible to use Form S-3 for this offering. Please see the cover page of the
prospectus where the following language has been inserted:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;As of February&nbsp;15, 2011, the aggregate market value of our outstanding common
stock held by non-affiliates was approximately $68,243,087.70 based on 46,595,562
shares of outstanding common stock, of which approximately 45,800,730 shares were
held by non-affiliates, and a per share price of $1.49 based on the closing sale
price of our common stock on February&nbsp;15, 2011. As of the date hereof, we have not
offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the
prior 12-calendar month period that ends on and includes the date hereof.&#148;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Please confirm that, in connection with each takedown of securities, you will file an amended
legal opinion as to the specific securities issued.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Response</I></U>: The Company hereby confirms that, in connection with each takedown
of securities, it will file an amended legal opinion as to the specific securities issued.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company hereby acknowledges that:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="center"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is responsible for the adequacy and accuracy of the disclosure in its filings;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="center"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Staff comments or changes to disclosure to Staff comments do not foreclose the
Commission from taking any action with respect to the filings; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="center"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company may not assert Staff comments as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please call Jeffrey P. Schultz at (212)&nbsp;692-6732 or the undersigned at (212)&nbsp;692-6774 with any
comments or questions and please send a copy of any written comments to the following parties:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt"><B>Joel I. Papernik, Esq.<BR>
Jeffrey P. Schultz, Esq.</B><BR>
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.<BR>
666 Third Avenue<BR>
New York, NY 10017<BR>
Phone: (212)&nbsp;935-3000<BR>
Fax: (212)&nbsp;983-3115
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Securities and Exchange Commission<BR>
April&nbsp;14, 2011<BR>
Page 3

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left"><I>/s/ Joel I. Papernik</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Joel I. Papernik&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">cc:</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Securities and Exchange Commission</U> (Jeffrey P. Riedler, Esq., Assistant Director)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Cyclacel Pharmaceuticals, Inc.</U> (Spiro Rombotis, President and Chief Executive Officer;
Paul McBarron, Chief Operating Officer, Chief Financial Officer and Executive Vice President,
Finance)</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y04704cy0470402.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04704cy0470402.gif
M1TE&.#EAS0`9`.8``*VKJ[2RL=73T9Z<F^;EY9&.CDQ)2OKZ^O/R\:6CHEQ9
M6(."@BTI*'Y\>\'`P&!=7'AV=$5#1.OIZ&UJ:<[+R,C&QM_=W55248J(B<"^
MO>CGY0L("5E65>[M[&5B8141$NGHYS8R,KZ]O.3CXG!M;$A%1#TZ.75Q<-?5
MU+RZN3@V-J&>G=K9V!P9&5!.3>+AX.WKZD$^/8%^?<;$Q,W,R[JYN/?V]L3"
MP?;V]:^MK-/1T-K8UY>4D]+0S\G(R/3T\R`='9F7EAH7%R4B(C`M+(J'AO#O
M[MC7UF)?7I*0D+JXMZNHI\+`OB@E)8:#@FMH9W)P;X6#A.+@W^#?W=;4T]'/
MSL7$PQ`-#L[,RX^-C%103Q(/$.?EXZFFI:NGI/KZ^?W]_?CX]_GX^/'P[_7U
M]/O[^_;U].[MZZJGIB4@'[BUM8Z,BYJ8E^?FY.7EY*BEH_3S\DM(1ZFGIH>$
M@X:$A2,?'WMX=VIH:,O)R-[<V]W<W#,O,):3DHR*B0<%!O___R'Y!```````
M+`````#-`!D```?_@'\H41B%&%%_B8J+C(DZAH4+98V4E9:7F)F:BQUVD)!L
MFZ*CI*6)5`HA?JM^!*-LK$`N4).FMK>F$A`<0ZQ^*@H)N,/$HR2L-:,*JQLL
MQ9D(-L^W84"K#+73VMM_#JP/HC=;JQ><7%PP?S#G"&7G9^[9C63G(.I<;7\D
M'E)AFB!,B/RI48(+@DOKTF&ZL(H.M'-D*K7A,L;&.1MBSG&I!(*+A#\3SWS1
M:(/>.3`=SGTY,^921RYP,G(QL\@;*Q2;D+!:L,A#&E]^&$Q@\I-5$DL)BK(B
M8B,&T*=0[?S!`+7JB4P<5O'(I.!*55\<5K0`RN`%)1->5P'Q@(?!!E\;_QA,
M.2&$59U+(=ZR:A%*D;<ZJR!H$G#EPRJ>C`*PFK%HQ(-5+91<DD#$CY81B:ZH
M6$%#@&<!X_SH^%PE@,XD8%QL:"!B]&?/>`S[\:`IJY^MF<KH]'/AM0`:"S0G
M>I.6RB4I#/P4R(9#Q2H78A25"5#7CPM,!=Z*:)3`CYVW0W9DTG)E-^+&S!I9
M8!5"PR4[?M8XVH"GD>Q&/[;PH`)$:J45J\2`&59:;=*='T]0\D03BBSCQP"7
MJ*$9&(P<XT<1C3CH!Q^7'`'$!Y3PX`<%):QRU24O^('$@0TTPL4J(#;B2PQ?
M6)+!;8E`@*%]JU"B0A!LF&#)$6]]@%-M!6KBQ?\J"39RPUV)J/$6@Y;<L4$*
MC2RP2@&--.!+`):TP8`*(8YXQ"I;Y&.)"7[0T,4U+L)(B1\+L.F'`994\"`F
M]Y6B@9U,B&(;;IDLB6`E1B@BA@NKT%`)&5>4D^6667X@`RN!5F)`!)1$X8<_
M3OD!3B4W'/IF4''Z$2,C#UI@YXF-"."'`WSV6(H'J[0H:)*%,JG)$JN04`D$
M&X`YJ7)9"B'``&HQ1LFFE&B92`IO7>%,(U^H-L4?IS*0ZJJ+^-'%'P+T<J$\
MB<A*ZR5]CC+`6R9$MRN.2OJZ"`X3--+!6!NX@2T02-1X+)>,+*#L'Y<&I<.S
MG#9"PA6*A,H!)4R(FDC_M]_..>X?-WCU01:QSEJK'Z3D4=?!HPRZB:%-*H(%
MR8TXL4H0C2BF1B5:(EOPP6`XR,!'C$#;"`="*)*`7D<P\H4"'P"-,2,OJJJQ
M(C>\52PCZHX\RA>5;0`A*2K7ZP<'&G%A00E`4$+`6S$TT@29.%.ZLP"*Q+%*
M'3\$W3`C%Q2=B!AV^Z$`(SEXI\C3BT0-KB+B+@+L*E8LDC6[MFZ2,!2FA-UK
M5=Y2$KAQBN@I6=PZ+V(PW8ET4*(?(>"PB-!!"Z1(X:MDL$@$#/AS,9Q0RRGC
MQHH4P$Q]Z8I,.<R:T$Z$0F#SBHFA6GR&108A=-Y(#ZO@J8@6+5R2,\&FHYR(
M_P3.6??ZWHN8@+X-JJA8RQL;@'PX*QG_SD@9PONQ1>3D&F])NYC`0A/\<(4>
MV$)SS[.7(M2`O$:HX@KN^4,5_+`$[\DM?*A3A`8JHR*!P6X1#$#?'VCW`=N!
M80\A<,7\*J<(Q<UI!8W`@87VX*C)_8^%EPB<_#+GO$NPC!%CN$XE\J>K!M3!
M=9;X7K(RJ(@=C,4/3J#0!Q7Q`1%6XSDCW-,B3M7`1+A01ABH!*."H@<;5@*`
MEK!0VVZ!0!\J<!-C:0$"6``$P5BP=(HX'24$(!OY3/$/"-B`"`?""NJD06`K
M]$/>$N<[5H61$F6(`(STM*X;=I$2+_.#'''11O4DXO^'HX#"*G*P@"WH+HD7
M5,03Q,>(&K"B#W^D@!\&^0=SO65TBQ`!*YCXAR\ZTA)D")57*GE&'#8"!G79
M@!PNP8)'6J*3BU!#C$!)B3!`X92)F&!0UI())3+B"1MP%B70P`Q!-J)PM#R0
M'XB`2+_LLG=28\0(5(0B2:Z"F)1`(Q`#)X-+_"`&+:N$;3!GB1*$X).K&-P0
MA=#.1(SQ"EC"A#<7\00_;,<20=#+(+T$MT8DQP]HH,3C_"#.1,S3#QMHQ,OV
M@(DC?!2?2@N-!2I1AH01P1XT78/_*F'/%N"T$5'8`$$!Y(<U-J("'QA58E:A
M!21>PD([6H06M%@),$!@%>C_PT$%!G@E2G@)2HR0PAU8,8$!_:$,Y%Q%!1>1
M!)0N[!)Z,`P`+G&CF56BK;GRS6<JL`(#$/`@E1A!`/3B!Q/P(`452.P,$F"A
M"N)`0W/HS&=HD(#DO)418?#*URX!ASVL(@Y._<,/K.$!P%H"5WO#*U"N`+1$
MT-&9B3A35:9P@;2PX@J#ZXHOMB"I2NC@"H1B1!ULNXHKI($1&2#L5\!2B1TL
M%RHQ6$)UGNL'L#9""UMHB252,%U6"($%(NBN'X3@`TO8X`%[L\A,SEJ/HU)"
M([70R!^,<(Y)N,,@\Z5((CJ2J$N(8*:4>`E->ND11IBAOI<X@$;DU0@P:&21
MC=!`)]G&H&`N_%01#BY;!RQ!`%Q6HL*`I2\7P)!A"OW@'`>XA!&,]8=````[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
